About 50 % of Type-1-Diabetics, 33 % Type-2-Diabetics and 75 – 80 % Mucoviscidosis patients develop exocrine pancreatic insufficiency in the course of their illness (Hardt PD, [...]
R-Biopharm AG has faced the challenge to develop a sophisticated allergy in vitro test system that combines both a quantitative determination and a very economic and easy handling.
R-Biopharm (Darmstadt) has brought to the market the fastest assay currently available for the specific detection of enterohemorrhagic Escherichia coli (EHEC). With the new RIDA®GENE EHEC/EPEC [...]
The Danish company REFLAB became a member of the R-Biopharm group on January 1, 2010. As a supplier of test kits for the detection of autoreactive urticaria and histamine release tests for the [...]
Your first step in the diagnosis of noroviral gastroenteritis outbreaks, powered by R-Biopharm Noroviruses, the most common cause of acute gastroenteritis are estimated to cause 21 million people [...]
